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Abstract 
The development of resistance by organisms to antimicrobials is a natural 
phenomenon.  Although it is increased by the use of antimicrobials, reduction in use 
of them will not necessarily reduce resistance, and there is a possibility that 
eventually most, if not all, antimicrobials will become largely ineffective.  However, 
current estimates of the economic burden are modest – at anything from less than 
£5 to more than £20,000 in reported additional costs per patient per episode for 
hospital costs, and anything up to around £10 billion per year in societal costs, they 
are far lower than estimates of economic burden from other health problems, such 
as cancers, heart disease and mental disorders. 
 
The reason that current estimates of the cost of resistance are modest is that they 
are based loosely on the ‘incremental’ cost related to the extra treatment of resistant 
over susceptible primary infection.  This masks the most critical economic burden, 
which is when resistance leads to the loss of many of the advantages in medical 
care that antimicrobials have enabled. For instance, advanced surgical procedures 
and cancer chemotherapy might become far more dangerous as rates of associated 
infection increase and cannot be treated.  The effective ‘removal’ of antimicrobials 
could mean soaring rates of post-operative infection, mortality and morbidity from 
what are currently considered to be trivial infections, presenting an apocalyptic blow 
to health system development.  The full economic burden of this is not only 
inestimable at present, but unimaginable.  It is therefore urgent that a full system 
analysis of resistance is undertaken. 
 
Rather than continuing the focus solely on the additional cost of treating an infectious 
disease in the presence of resistance, what is needed now is to look at how health 
services more broadly might be affected if resistance becomes endemic, and the 
wider implications of this to society.  Incentive mechanisms also need to be 
developed at a number of levels, and could require radical change, such as moving 
to more restrictive prescription (for example, through a hospital setting only, 
removing the ability to prescribe from primary and community care).  Clearly the 
necessity of, and ability to implement, such radical change will need to be informed 
by the system analysis, and also supported by it when it comes to engaging the 
wider political and popular support that would be required. 
 
In needing to consider a system approach, resistance shares many of the 
characteristics of climate change.  Both provide future significant threats to human 
well-being, both are subject to considerable uncertainty about their future extent and 
trajectory, both are global problems where the response differs across nations, and 
both have as an underlying cause the over-consumption of ‘goods’ that lead to short 
term benefit.  Yet for both there is considerable inertia to major, radical, change 
because there is a focus on current burden and because the personal incentives 
seldom match those of society more generally. 
 
However, there appears to be increasing scientific consensus about the impact of 
global warming in a way that is perhaps less clear – or at least less coherent – for 
antimicrobial resistance.  For global warming this has led to clear, simple and 
consistent messages from the scientific community, underpinning increasing 
acceptance of the desirability of action by a broader policy-making community 
including politicians, economists and philanthropists.  For antimicrobial resistance 
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there is a clear danger that waiting for the burden to become significant before taking 
action may mean waiting until it is too late to stop an apocalyptic scenario – the very 
drive behind the early environmental movement’s advocacy of the ‘precautionary 
principle’. 
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Introduction 
The ability of organisms to develop resistance to the effects of antimicrobial 
therapies developed to kill them is potentially the greatest challenge to healthcare in 
the 21st century.  It increases the threat not only of primary infectious diseases such 
as tuberculosis, but also secondary infections associated both with other diseases 
and the provision of healthcare itself (1).  Modern healthcare was built over the last 
century on the basis that infections can be prevented or treated using antimicrobials 
(exemplified by the U.S. Surgeon General famously proclaiming in 1968 that “the war 
against diseases has been won”) (2).  During this time healthcare has become 
increasingly technological and invasive, improving mortality and morbidity 
significantly.  Yet, many of these advances, especially within surgery, radiotherapy 
and chemotherapy, are based on the ability to prevent or cure infection that may 
result as a consequence of such care.  The emergence and transmission of 
resistance threatens to undermine many of these advances (3). 
 
This paper is focused upon examining the economic burden that results from 
antimicrobial resistance (AMR).  In so doing, it highlights the ‘temporal tension’ 
between the burden observed in the present and that which may be predicted for the 
future.  Although the paper presents evidence about the current economic burden of 
AMR, the main focus of the paper is on developing a hypothesis concerning the 
likely future trajectory in this area and the significant implications of that trajectory. 
 
The paper highlights the critical problem with the current emphasis on using 
economic burden as evidence for directing future investment in health issues, as well 
as difficulties related to methodologies available for estimating such burden.  The 
paper concludes by considering the policy implications as well as the key 
research/evidence gaps and the challenges associated with filling those gaps. Note 
also that we are concerned here with human use and human health – there are 
critical links with animal use and health (eg 8), but we do not have space to consider 
these in this report. 
 
A brief history of AMR 
Before looking at the current economic burden of AMR, however, it is worth 
reminding ourselves of the history of AMR.  Resistance may be seen as essentially a 
reaction to the use of antimicrobial treatments.  Although the process of natural 
selection encourages micro-organisms to adapt to environmental pressures, the use 
of antimicrobial therapies can accelerate this natural process, whereby sensitive 
micro-organisms are soon eliminated by resistant ones (4).  Although there remain 
uncertainties over the development of resistance, the ‘genetic cost’ to the organism, 
and the extent to which resistance is temporary or permanent, there is concern that 
over time there is no reason to suspect that resistance will not occur to all 
antimicrobials; the only question is to what level (5). 
 
Resistance means that an antimicrobial therapy is no longer (as) effective against 
the organism it is targeting.  For any particular antimicrobial, the correlation between 
consumption and resistance is complicated by many factors, including the relative 
‘fitness’ of sensitive and resistant strains, together with the existence of genetic 
elements simultaneously coding for resistance to several antimicrobials.  This is 
important, as simply reducing the consumption of a specific antimicrobial cannot 
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necessarily be relied upon to produce an equivalent reduction in resistance, and thus 
once the effectiveness of an antimicrobial is ‘lost’ it may be lost forever (6). 
 
This has been known since the 1940’s, when the development of resistance to 
penicillin was documented just after it was discovered (7). 
 
The current situation 
So, given this history, why is the level of concern increasing now?  It is because the 
increase in organisms resistant to multiple therapies is now coinciding with the 
reduction in new therapies coming to market to replace ineffective ones. 
 
That resistance develops to an antimicrobial therapy is not itself a problem – and as 
indicated is merely a natural process, albeit accelerated by use of these therapies – 
as long as there are other therapies to take its place.  During the latter half of the 20th 
century this was the predominant situation.  Over this period the various classes of 
therapeutics, and the specific therapeutics within these classes, were discovered 
and the antimicrobial ‘armoury’ was added to on a regular basis (9, 10).  However, 
the pipeline is almost dry.  Between 1983 and 1992, 30 new antibiotics were 
approved in the USA, but only seven have been approved since 2003 (11).  Between 
1968 and 2000, no new classes of antimicrobial were discovered, and although two 
classes were discovered in 2000 and 2003 it is worth noting that these targeted only 
gram-positive bacteria; there remain no new class candidates for gram-negative 
bacteria (see figure 1) (12). 
 
FIGURE 1: DRUG DISCOVERY 
 
In 2004, only 1.6% of drugs in development by the world’s 15 largest drug 
companies were antimicrobials (9, 13).  A recent report from the European Centre for 
Disease Prevention and Control and European Medicines Agency identifies only two 
new drugs under development, both of which are in the early stages when failure 
rates are high (14).  There have been many options proposed and discussed to try to 
encourage greater research and development in antimicrobials (15), but it has 
recently been voiced that “today’s dearth in the antibacterial research and 
development pipeline will take decades to reverse” (16, p1091) and that “the existing 
classes of antibiotics are probably the best we will ever have. We are wary of 
creating an expectation that economic incentives can generate a pipeline to 
compensate for our squandering of this non-renewable resource” (17, p1). 
 
At the same time that the number of new therapeutics has been declining, organisms 
such as S. Aureus and E. faecium have been acquiring resistance to multiple 
therapies (18).  Consider, for instance, Multi-Drug Resistant Tuberculosis (MDR-TB); 
defined as resistance to at least isoniazid and rifampicin.  The incidence and spread 
of MDR-TB is of concern to both the developed and developing world (19).  For 
example, in the USA, MDR-TB epidemics have been reported in New York and 
Florida (20), while in Africa the incidence of MDR-TB continues to spread 
dramatically and extensively (21). 
 
This imposes a significant resource burden as the associated treatment costs are 
substantial, with some patients in the USA costing approximately $US1 million each 
to treat (22).  And this is where there is still some other therapy as an option.  Where 
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there are cases of totally drug resistant (TDR) infection there are no therapies that 
will provide an effective treatment; this is now the case for vancomycin-resistant 
Enterococcus faecium (18, 23).  The rapid spread of any such organism is a clear 
cause for concern; antibiotic resistant bacteria do not stop at national boundaries 
and antimicrobial resistance is a global issue (24, 25). 
 
To sum, organisms develop resistance to antimicrobials, and increasingly are 
developing resistance to multiple therapies, rendering these antimicrobials 
ineffective.  At the same time, the once prolific pipeline bringing new antimicrobials 
into clinical practice is faltering. We are therefore at a pivotal stage in the history of 
infectious disease, where the window of opportunity afforded by antimicrobial 
therapies over recent decades is rapidly closing (3). 
 
Current activities 
Clearly there has been progress, especially in recent years, in practice and policy 
concerning more conservative and appropriate use of antimicrobials in the attempt to 
halt or slow the progress of resistance.  There are various policy, public and 
professional reports and strategies (12, 26-29) highlighting the problem, and 
suggesting a range of activities and strategies, many of which have been 
implemented. In the UK, the first Antimicrobial Resistance Strategy, published in 
2000, had three inter-related key elements – surveillance, prudent antimicrobial 
prescribing and infection control, and these aspects are still relevant today. 
 
Work, such as that in the UK, is enabling us to become better custodians of 
antibiotics, reshaping the debate on how to control AMR. This has involved 
encouraging better diagnosis, medicine management and use of therapeutics by 
promoting the prudent use of antimicrobials and educating healthcare workers to use 
antibiotics more appropriately (i.e. only when needed, ensuring correct dose and 
duration for treatment), as well as promoting good infection control (e.g. hand 
hygiene, screening, patient isolation) to prevent and control AMR. These 
interventions have been informed by surveillance activities.  This work has helped to 
strengthen surveillance, infection prevention and control, and to promote the 
responsible use of antimicrobials in the UK.  It can be expected to have an impact on 
the containment of antimicrobial resistance. 
 
Why these are not sufficient 
Although there have been positive changes, and many within the scientific 
community are now convinced of the need for action, the question is whether 
interventions such as these remain marginal in relation to the total size of the 
problem, with insufficient impact on reductions in antimicrobial use to change a 
future in which the loss of effective antimicrobial therapies is inevitable.  This 
question of marginality is pertinent both to the within-country context (is there 
sufficient reduction in usage in one setting such as the UK?) and the cross-country 
context (is there sufficient reduction in usage globally?).  The core problems, of 
widespread use, rapid transmission and lack of new product development, remain.  
In this respect, incentives continue to be the major concern at all levels. 
 
As indicated above (figure 1), there has been an almost total shutdown in new 
product development.  Notwithstanding whether the possible compounds for 
discovery have been exhausted, this is unsurprising; there are few incentives for 
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pharmaceutical companies to develop a new drug for which health systems will aim 
to restrict use (11) and thus potential profits.  This is particularly true within the 
current system for incentivising R&D into new therapies – the patent system targeted 
at private companies – where companies wish to sell as much as possible as quickly 
as possible to generate revenue and recoup development costs.  In restricting the 
use of new antimicrobials until absolutely necessary, it would be likely that the major 
use of such ‘saved’ drugs would be after the end of the patent period.    
 
Similarly, there are incentive problems with achieving conservative use of 
antimicrobials.  For each individual who wants to take an antimicrobial to feel better, 
the impact on resistance of their specific antimicrobial use is virtually unidentifiable, 
making it very hard to enforce a substantive reduction in use, even in areas deemed 
‘inappropriate’ (30); in this respect the antimicrobial problem is identical to that of 
global warming, where the contribution of each car journey, for example, is minimal 
but the sum of all such journeys is substantial. 
 
There are also incentive problems for policy makers.  There is growing emphasis on 
evidence-based policy making, which includes considering the economic burden of 
disease, and the demonstrated cost-effectiveness of therapies.  Put simply, this way 
of informing policy requires burden to be high now in order to justify expenditure on 
new drugs, and especially to justify it on the basis of cost-effectiveness, and the cost 
of resistance needs to be high now to justify greater restriction on use of current 
drugs (31).  Note the emphasis on now. 
 
However, as outlined below, evidence to date is that AMR has only a comparatively 
minor cost impact.  There are, of course, considerable parallels here with wider 
aspects of prevention versus treatment when health budgets and results are 
expected to focus upon the short term, and at the mercy of the political cycle, which 
encourages group myopia (32).  Nonetheless, in the case of resistance this is more 
pronounced and arguably, since once resistance develops it may be irreversible, 
more important. 
 
Evidence on current economic burden 
Qualitatively we know that treatment failure caused by AMR contributes to increased 
costs of care associated with: additional investigations such as laboratory tests and 
X-ray examinations; additional or alternative treatments, often much more expensive 
than drugs used to treat infections caused by sensitive organisms; additional side-
effects from more toxic treatments, which have to be managed; longer hospital stay; 
longer time off work; reduced quality of life and productivity; greater likelihood of 
death due to inadequate or delayed treatment, hence reducing the workforce; 
increased burden on family of infected individual; increases in private insurance 
coverage; additional cost for hospital when hospital- acquired infection occurs and 
infection control procedures required; increased costs of disease surveillance; 
increased costs to firms of absenteeism, possibly leading to increased product 
prices; and so forth (1, 33, 34).  And this is not including costs associated with 
surveillance and activities associated with trying to control resistance itself. 
 
Yet, quantitatively, the problem is that, far from illuminating the burden of resistance, 
this translates into a vast range of figures depending upon what precisely is 
assessed.  Cost estimates will depend on, for instance, whether assessment is at the 
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level of the individual or (multiple) institutions, whether figures are based on 
comparison of a resistant versus susceptible patient/infection or they are total costs 
of care (resistant versus nothing), whether figures include hospital costs only, look at 
patient costs, or incorporate productivity costs (i.e. consider the health care or the 
‘societal’ perspective), and the methods used to estimate these costs, whether they 
are focused on one or multiple disease areas, and whether preventative control 
measures are included (35, 36).  This lack of consistency or comparability of 
methods used to assess economic impact generates problems in assessing the true 
scale of the problem, as discussed further below. 
 
An important, although now dated, review of these studies found that patients 
infected with resistant organisms generally had poorer health and economic 
outcomes than those patients with susceptible organisms (37).  A more recent 
review has shown higher costs, in the order of $6-30,000 per patient per episode for 
resistant compared to susceptible S. aureus, enterococci and gram negative bacilli 
(38).  This latter review noted that evidence suggests though that there are not big 
increases in cost, resource use or mortality from resistance; a finding backed up in 
other recent studies (39, 40). 
 
Updated literature review 
We also previously undertook a systematic literature review concerning the 
economics of AMR, summarizing studies focusing upon the costs of resistance 
published up to 2000 (35).  This review focused both on costs of AMR and the cost-
effectiveness of control strategies.  It found a total of 43 studies, although 22 were 
categorised at high risk of bias and excluded from analysis.  Of the 21 remaining 
studies, most were from the USA and hospital based.  In terms of costs of 
resistance, most indicated areas of resource impact rather than reporting monetary 
values, and those that did report monetary values produced wide variances, 
although all well below £100,000 per annum per institution. 
 
For this current paper, we updated these searches to focus on papers published 
since 2000 which reported the cost impact of resistance in English-language, peer-
reviewed journals, where we could extract any or all of length of stay, mortality, 
patient cost and/or societal cost that may be attributable to AMR.  The focus of this 
updating review, in line with the DH brief and the focus of this paper, was the 
economic burden of resistance; it excluded review of the literature on the cost-
effectiveness of alternative control strategies which is concerned with policy options 
for dealing with the issue, rather than the nature of the issue itself. 
 
Initial searches were only conducted on combinations of resistant/ce, antimicrob/ial 
and cost/s; as it became clear that papers that did not refer to antimicrobial 
resistance more generally, but only to either particular drugs or particular micro-
organisms (an indicator of a much more fundamental problem, to which we return in 
the discussion), would not be captured in this search, a subsequent search focused 
particularly on MRSA and VRE, as two of the most studied and potentially more 
serious current resistant infections.  These studies are summarized in table 1. 
 
TABLE 1 
SUMMARY OF COST DATA 
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The studies listed in table 1 are consistent with previous reviews, indicating three key 
findings that appear robust to change over time. 
 
First, there are a vast range of figures, from less than £5 to more than £20,000 in 
reported additional costs per patient per episode for hospital costs, and anything up 
to around £10 billion per year for full societal costs.  These figures are largely 
determined by whether and how productivity losses are incorporated (12, 41-43). 
 
Second, most studies originate in the USA.  This may be a reflection of the English-
language journals included in the search, but such a degree of national dominance is 
still unusual.  Given the very unique nature of the US health system, and its financial 
structure, these costs are unlikely to be indicative of other systems, such as the UK. 
 
Third, there is a heavy predominance of hospital-based studies, and indeed the 
costs are almost exclusively related to costs of additional hospitalization/treatment 
and do not include costs associated with early mortality; from an economic 
perspective this almost certainly underestimates the cost.  There is only one UK 
empirical study, which also happens to be one of only two community studies, and 
one UK study that is the only one to apply a macro-economic modelling technique 
(43).  Whilst hospital costs are inevitably higher on a per patient basis, there may, 
however, be significant unassessed costs among patients infected with resistant 
strains who remain in a community setting, where even a small increase in costs at 
the individual level may, because of higher prevalence, result in a relatively high 
burden on the community overall (44-46). 
 
Overall, in sum, although there has been a substantial increase in studies over the 
last decade compared with prior to 2000, there remains a low, selective and widely 
divergent evidence base concerning ‘the economic burden of AMR’. 
 
The case of MRSA 
An interesting case study here is clearly that of MRSA versus MSSA.  This is 
summarized in Box 1 and two conclusions are apparent.  First, there is a very wide 
range of costs.  Second, even at the high-end, the costs remain quite modest.  It is 
worth noting, however, that unlike some of the resistant gram-negatives currently 
emerging, there remains a choice of therapy available to treat MRSA. 
 
BOX 1: A CASE STUDY OF MRSA 
 
The relatively low cost for MRSA is reflective of AMR more generally, as illustrated in 
table 2.  This table provides estimates for various disease areas, standardized to 
2004 US$bn, compared with the current highest estimate found for the societal cost 
of AMR to the USA in 2011 by CDC.  At approximately $55bn ($20bn health service) 
per year, AMR still rates quite low in the league table of disease burden for the US. 
 
TABLE 2: 
COMPARATIVE ECONOMIC BURDEN 
 
The paradox of the relatively low level of economic impact 
Current evidence therefore suggests that the economic burden from AMR is actually 
quite modest, even though AMR is acknowledged to be a significant threat to health 
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and healthcare.  This apparent inconsistency might arise because current estimates 
of the cost of AMR are based loosely on the ‘incremental’ cost related to the extra 
treatment of resistant over (actual or assumed) susceptible infection.  These costs, 
broadly speaking, increase as we see multi-drug resistance (MDR) emerge (such as 
in the case of MDR-TB (47)), but at present organisms that are MDR remain 
relatively rare and often occur in isolated outbreaks.  The highest costs – if we 
exclude productivity losses, discussed in the next section – are those where 
organisms are totally resistant, where no therapy is effective creating high service 
use and the eventual death of the patient.  In these very rare cases the cost is of a 
magnitude higher as we are looking at intensive (and often terminal) care, rather 
than merely a little extra length of stay or another slightly more expensive therapy. 
 
These latter cases are an indication of the potential future cost associated with 
increasing types of resistant infection and increasing transmission of those 
infections, as once there are no therapies that are effective, mortality, morbidity and 
the associated economic burden may take a quantum leap; not just in the treatment 
of primary infection, but critically as routine procedures are severely compromised by 
untreatable secondary infection.  (An example of such a situation is extensively drug-
resistant tuberculosis (XDTRB).  Whilst a recent study in the UK found that the 
numbers infected with XDRTB were still small, it also identified extremely high 
mortality rates in the order of more than 60% (47).) 
 
The economic consequences of AMR outlined in the papers reviewed relate only to 
the direct impacts of resistance itself on the ability to treat primary infections; which, 
as indicated, tend to be incremental.  Of potentially greater importance is the more 
indirect future impact that resistance may have on the ability of the health service to 
deliver other forms of healthcare in the presence of increasing rates of secondary 
infection.  Here there is no evidence that we are aware of.  Before moving on to 
consider this issue further, however, it is worth reflecting upon the limitations of 
attempting to assess the current burden of AMR. 
 
Limits of assessing ‘costs of resistance’ 
A standard ‘cost-of-illness’ approach will not capture the true nature of the costs of 
AMR for three reasons.  First, AMR is a negative externality associated with 
consumption of antimicrobials (32). That is, it has an undesirable effect which is 
distant from the current consumption decision.  This distance arises in two ways.  
First, consumption of an antimicrobial will contribute to organisms generating 
resistance to its effects, and thus other people will suffer from reduced effectiveness.  
Second, that lower effectiveness will impact on the original consumer, but in the 
future not the present1. 
 
The problem is that the externality effect from each antimicrobial consumed is 
miniscule, especially once the future effects are discounted (30).  Thus, even if it 
were possible to increase the cost of consumption (e.g. price of antimicrobial, or cost 
of prescription) to incorporate some value of externality (the standard economic 
approach), it would only be extremely minor for each individual decision and highly 
unlikely to induce any reduction in consumption (48).  So, the externality effect 
                                                 
1 There is also a third externality across country.  We do not cover this in this paper, but the interested reader is 
referred to references 24 and 25. 
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means that the cost of resistance is not reflected in current prices, but even if it were 
it would be so minor for each individual consumer that it would not cause an impact 
on consumption (33). 
 
Second, the specific sigmoidal pattern of the development of resistance, illustrated in 
figure 2, means that the cost will be low when there is scope to prevent resistance 
emerging (as quickly) but once it is observably high there may be little that can be 
done to prevent the transmission of a heavily resistant organism.  That is, in general, 
the development of resistance over time appears to follow a sigmoid (or epidemic) 
distribution, with a lag phase before resistance appears (time x), then a relatively 
rapid increase in the proportion of resistant organisms, followed by a third phase 
(time x+n) in which this proportion reaches an equilibrium (49). 
 
This equilibrium level is determined by the relative ‘fitness’ of resistant and sensitive 
strains, the genetic basis and stability of resistance and the magnitude of the 
selection pressure (50).  Thus, the cost during the lag phase when resistance is low 
– approximated by most studies to date – is correspondingly low, and vice versa 
once resistance is high, but the critical point is the phase of rapid advancement, 
where the ‘epidemic’ of resistance may be such as to be unstoppable.  Where we act 
determines whether we are looking at prevention of excessive resistance or 
mitigation of high levels. 
 
FIGURE 2: SIGMOIDAL DEVELOPMENT OF AMR 
 
The critical implication is that this uncertainty regarding current and future burden 
combined with discounting of future benefits means that strategies to reduce 
transmission are far more likely to appear cost-effective than strategies to control 
emergence, hence reinforcing the status-quo (30, 32, 33). 
 
Third, estimates of cost-of-illness tend not to focus on less direct costs associated 
with the impact of resistance on patient safety or public confidence in health care 
institutions.  Public and media concerns frequently focus on the plight of individuals 
who suffer what is seen to be ‘avoidable’ infection within a context where the 
institution is empowered and the patient is both vulnerable and dependent. There is 
therefore a cost to maintaining public confidence in healthcare providers and 
institutions. 
 
The future? 
Antimicrobials are the cornerstone of modern medicine that revolutionized healthcare 
during the last half-century. From cradle to grave, the role of antimicrobials in 
safeguarding the overall health of human societies has become pivotal. So the ‘real’ 
costs of AMR are those that relate to the loss of these benefits; the treatment 
possibilities at every stage of human life that have been enabled and enhanced 
because of antimicrobials.  We know, for example, that MDR bacteria have 
increased mortality rates amongst newborn babies (51-55), transplantation recipients 
(56-58) and cancer patients (59, 60), but we do not know very much beyond these 
few isolated case studies, and know nothing about their economic implications. 
 
Thus, in order to calculate the full potential economic burden of AMR we have to 
consider the burden associated with not having antimicrobial therapies at all.  To our 
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knowledge, this has not been attempted.  We have therefore provided an illustration 
in Box 2.  Although this is a greatly simplified illustrative example of one specific 
area, relating to hip replacements, it indicates the complexity involved in attempting 
to assess the true level of the likely economic burden of AMR.  However, despite this 
complexity, we would suggest that this form of analysis – for the health system 
overall, not just specific diseases – is the single most important step in 
understanding the likely future burden of AMR in order to assist with planning, 
resource allocation and policy making with respect to the development and use of 
antimicrobials today. 
 
BOX 2: CASE STUDY HIPS 
 
The ‘true’ cost of AMR 
It has been said that AMR presents a risk that we will fall back into the pre-antibiotic 
era (3).  However, this is perhaps a more rosy picture than the reality.  The health 
system has changed fundamentally over the last 60 years, with antimicrobials 
integrated in almost all aspects of care.  The system is designed to treat more 
chronic conditions, provide treatments on a short-term – often day-case – basis, and 
encourage prevention.  As Box 2 illustrates, in many cases antimicrobials are given 
as a matter of standard prophylactic care.  As witnessed when there are outbreaks of 
hospital-acquired infection, the system can very quickly come to a standstill (61).  
The removal of antimicrobials could mean soaring rates of post-operative infection, 
mortality and morbidity from what are currently considered to be trivial infections – in 
the case of hip replacement illustrated in Box 2, this would be an increase in deaths 
from approximately 0% to 30%2. 
 
Multiplied across all the hundreds of clinical areas where antimicrobials are currently 
used, it can easily be envisaged that this will not only be a significant health burden, 
and present increased healthcare cost (inpatient stay) itself, but would present a 
catastrophic blow to health system development – for instance, requiring redesign of 
many facilities, the reintroduction of sanatoria and so forth.  The full economic 
burden of this is not only inestimable at present, but unimaginable.  Increasing rates 
of infection to the level this would also have enormous wider economic impacts 
(significant workforce impacts (62)).  However, at present, this is speculation, and 
there is an urgent need to more rigorously investigate the potential future 
consequences for health systems more generally from the impacts of resistance. 
 
Conclusion 
We are entering a pivotal period where, if current trends continue, there could be 
highly significant costs to healthcare, and society more generally, as antimicrobials 
that form the basis of modern healthcare become increasingly ineffective.  As AMR 
is a natural process, we are not looking at something that can be ‘eradicated’; rather, 
it is something we have to manage if we are to continue to benefit from antimicrobial 
therapies (63, 64). 
 
Effective antimicrobials therefore need rediscovering as a scarce – and largely non-
renewable – resource (3).  This requires an assessment of the balance between the 
                                                 
2 Of course, in practice, at such rates the expectation is simply that the rates of hip replacement would 
dramatically fall, and thus increase the burden of morbidity from higher levels of hip pain. 
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positive effects of using antimicrobial therapies now, and the negative impact of this 
use on their temporal effectiveness, and hence assessment of the optimal use of 
antimicrobials over time.  As with other areas of prevention, and issues such as 
global warming, we need to pursue a path that does not place undue emphasis on 
current burdens and costs, but reflects the importance of stewardship for the future.  
The presents us with three challenges. 
 
Reducing uncertainty and increasing knowledge of full health system impacts 
We know the current economic burden is relatively low compared with other 
problems.  Yet we do not know to what extent the future burden will grow, or how 
quickly.  We also do not know whether an increasing burden will give impetus to new 
technological change outside the drug arena that might mitigate effects.  (For 
instance, dealing with climate change involves reduction in car use, but also making 
cars more efficient, and we ‘solved’ the issue of Chlorofluorocarbons (CFCs) and 
ozone depletion by simply replacing all CFCs with non-damaging gases in air-
conditioning and refrigerator units.) 
 
Here, alternatives to antimicrobials include vaccination, but could also include 
structuring of care such that infection is less likely, for example changes to 
ventilation systems, bed spacing and so on.  We are therefore faced with 
considerable uncertainty, but uncertainty that suggests we need to incur some 
(perhaps considerable) cost now associated with current reduced use of 
antimicrobials, in the expectation of some future, indeterminate but likely far greater, 
cost being averted.  To judge the scale of ‘acceptable’ cost now, however, we need 
much better information about both likely future trajectory and the cost implications 
under different trajectories. 
 
A key research need is thus to estimate the impact of widespread resistance to the 
health system overall, and to wider society.  The current focus, on the additional cost 
of treating an infectious disease in the presence of resistance, needs to be 
complemented by looking at how services such as those relating to cancer care, 
heart disease and diabetes might be affected.  Such research will be a challenge not 
just in funding terms but in terms of bringing together those with the relevant 
expertise, ensuring that they can ‘talk to each other’ and developing methods that 
can both identify crucial gaps in the information base and, ultimately, provide robust 
estimates. 
 
Developing better, more radical, incentive mechanisms 
There needs to be an improvement in the incentive mechanisms at a number of 
levels.  In terms of the development of new antimicrobials, if new therapies are 
discovered then they need to be protected, and hence the use of them discouraged.  
New options are needed that can discourage high levels of use whilst avoiding 
disincentives for private sector R&D into new therapies, such as greater public-
private partnering, pre-purchase agreement, or direct public funding, which seems to 
be occurring at present but, compared with current estimates of costs of discovery to 
market, remain small (13, 15). 
 
In terms of individuals and their choice about whether to take antimicrobials, more 
needs to be done to balance the personal cost (minimal in the UK, and largely 
related to accessing a consultation, collecting a prescription and possible side 
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effects) with the true societal cost.  Some thought has previously been given to such 
mechanisms (48, 62) but none has been sufficiently developed to be of practical use, 
and all have potential difficulties.  More work is required here, and it may be that 
radical strategies should be considered, such as moving to more restrictive 
prescription (for example, through a hospital setting only, removing the ability to 
prescribe from primary and community care) for some or all antimicrobials currently 
widely prescribed. 
 
The acceptability of such restrictions may, of course, be related to whether the 
research discussed above is sufficiently robust to sustain such developments.  
Implementation of any radical – rather than currently marginal – strategies would 
require considerable public support to be politically acceptable, and in this respect 
much may be learnt perhaps from the environmental movement, as discussed 
further below. 
 
Enhancing international activity 
As is apparent from the review of costs, the issue of antimicrobial resistance is not 
confined to the UK.  International activity may be key to encouraging the 
development of new drugs and diagnostics to help control multi resistant bacteria.  It 
may also be vital to research to increase understanding of resistance mechanisms, 
cost trajectories, and means of controlling resistance in the absence of new drug 
developments.  There is appreciation of this issue in the UK, where a multi-pronged 
integrated UK strategy is under development (building on previous work and taking 
account of developments at EU and international level) and where championing the 
issue at EU and international levels is also an important focus. 
 
It is also important, however, to consider the extent to which a UK strategy needs to 
account for the likely success or otherwise of such championing, given that countries 
may have some incentive to free-ride on the actions of others, and given that outside 
influences may well affect the likely trajectories anticipated in the research described 
above (24, 25). 
 
Lessons from climate change 
As alluded to earlier, AMR, as a policy target, shares many of the characteristics of 
climate change.  Both provide future significant threats to human well-being, both are 
subject to considerable uncertainty about their future extent and trajectory, both are 
global problems where the response differs across nations, and both have as an 
underlying cause the over-consumption of ‘goods’ that lead to short term benefit.  
Yet for both antimicrobial resistance and climate change there is considerable inertia 
to the major, radical, change required to move from mitigation to prevention, 
because there is a focus on current burden and because the personal incentives 
seldom match those of society more generally. 
 
There do appear to be some differences, however.  In particular, there appears to be 
increasing scientific consensus about the impact of global warming in a way that is 
perhaps less clear – or at least coherent – for antimicrobial resistance.  Clear, simple 
and consistent messages from the scientific community have been vital in 
developing the increased acceptance of the desirability of action on global warming 
to a broader policy making community including politicians, economists and 
philanthropists.  This consensus, along with sustained and high profile campaigns 
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and the impact of positive media attention (including Hollywood movies), has 
increased public support.  Combined  with simple messages on what individuals can 
do (e.g. ‘reduce, reuse, recycle’), this has moved climate change into the 
mainstream of activities – to the extent that many aspects of individual action are 
now routine (e.g. recycling, house insulation etc.).  The issue of resistance does not 
seem to have captured the public imagination, attention or support for change to the 
degree that global warming and the environment has. 
 
For antimicrobial resistance there is a clear danger that waiting for the burden to 
become significant before taking action may mean waiting until it is too late to stop 
an apocalyptic scenario – the very drive behind the early environmental movement’s 
advocacy of the ‘precautionary principle’. 
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Figure 1: DRUG DISCOVERY 
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FIGURE 2: SIGMOIDAL DEVELOPMENT OF AMR 
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BOX 1: CASE STUDY OF MRSA 
Methicillin-resistant Staphylococcus aureus (MRSA) represents one of the biggest 
therapeutic threats, and is an area where much economic assessment has occurred 
to date (see table 1). It provides a compelling case study of the genetic adaptation of 
an organism into a first-class multidrug-resistant pathogen.  Following the 
introduction of penicillin, and later methicillin, S. aureus quickly developed resistance 
and by 2003 more than 50% of S. aureus isolates recovered in U.S. hospitals were 
resistant to methicillin. This was soon followed by low-level resistance to vancomycin 
(designated VISA) - vancomycin intermediately resistant S. aureus). Next, strains of 
MRSA with high-level resistance to vancomycin (VRSA - vancomycin-resistant S. 
aureus) emerged.  More critically, VRSA is often a multi-drug resistant organism – 
resistant to multiple drugs, including clindamycin, aminoglycosides, trimethoprim–
sulfamethoxazole, rifampin and fluoroquinolones. 
 
MRSA has also recently emerged as an important cause of community-associated 
infections.  Although several compounds have been developed, or resurrected, to 
treat gram-positive infections such as S. Aureus, none have been shown to work 
better than vancomycin, all have important toxic effects, and resistance to each has 
already been observed (including linezolid-resistant VRE in patients who have never 
received the drug) (18). 
 
In economic terms, illustrated by table 1, MRSA adds around $20,000 per patient per 
episode to the cost of hospital treatment in the USA (65, 66). In Europe, MRSA is the 
most common, single, multidrug-resistant bacterium, with an estimated 25,000 
patient deaths per year, approximately 2.5 million extra hospital days and extra in-
hospital costs of more than EUR 900 million (12). 
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BOX 2: CASE STUDY HIPS 
The problem facing any attempt to estimate the impact of removal of antimicrobial 
therapies is data from such a situation; such therapies are, and have been, part of 
routine care ever since hip replacements became available, both as prophylaxis and 
as treatment for HAI.  In an attempt to think laterally, we therefore looked at 
information relating to amputation – another major surgery involving limbs – as a 
proxy for what rates may have been pre- and post-antimicrobial discovery.  We used 
this information, together with current studies looking at the infection pathway for hip 
replacement, to construct and suggest possible values for the flow of patients 
requiring hip replacement, illustrated below. 
 
 
Here we have patients undergoing total hip replacement (THA) having prophylaxis or 
not, and from this having infections or not, being treated or not, and rates of 
effectiveness translating to final outcomes.  Currently, prophylaxis is standard 
practice so approximately 100% of patients follow route 4 rather than 5.  Infection 
rates, at 6, are approximately 0.5-2%, so most patients go down route 7.  Most of 
those following 6, go to 10 and have further treatment which is successful.  Most 
patients therefore exit at 15 or 18 (>99%). 
 
If we estimate this flow with no antimicrobials, we are therefore restricting 
possibilities to route 5, and for those at 8, route 13 – and hence end states of 21, 22 
or 23.  Here, at point 8 rates of post-operative infection are around 40-50%; of these, 
30% go on to die – state 21 (67-70).  Thus, removal of antibiotics can be estimated 
to lead to an increased in post-operative infection from approximately 1% to 50%, 
and deaths from approximately 0% to 30%. Of course, at such rates the expectation 
is simply that the rates of hip replacement would dramatically fall, and thus increase 
the burden of morbidity from higher levels of hip pain. 
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Clearly this represents a very crude estimate, for just one clinical area using 
antibiotics, but indicates the form of analysis required if we are to move towards 
beginning to estimate the full, true, economic burden of future AMR, with the removal 
of the option of antimicrobial therapies from a number of treatment pathways, both 
urgent and elective. 
Table 1: increased resource use and cost associated with infection with resistant rather than susceptible micro-
organisms: recent studies (published since 2000) providing data about length of hospital stay, mortality and/or additional 
cost. 
 
Author, year, 
reference 
Country of 
Origin 
Bug/Drug Year of Cost 
Data 
Increased 
LoS 
Increased 
mortality 
Additional per 
patient cost 
Additional 
societal cost 
Bhavnani SM 
et al, 2000 
(71) 
USA VRE n/a  +25% 
(p<0.001) 
  
Webb M et al, 
2001 (72) 
USA VREf 1996 + 5 days 
(NSD) 
+0.24 per 
hundred days 
of 
hospitalisation, 
(NSD) 
+$252/day 
(SD), or 
+$40,596 per 
patient 
 
Brooklyn 
Antibiotic 
Resistance 
Task Force, 
2002 (73) 
USA S. Aureus, 
Klebsiella 
pneumoniae, 
Acinetobacter 
baumannii, 
Pseudomonas 
aeruginosa 
n/a +4 days, 
p=0.04 (SA), 
+18 days, 
p=0.03 (KP), 
+18.5 days, 
p=0.014 (AB), 
+13.5 days, 
p=0.002 (PA) 
(all medians) 
   
Cosgrove SE 
et al, 2002 
(74) 
USA Enterobactor 
species 
1997 +10.5 days, 
p<0.001 
(unadjusted), 
+9 days, 
p<0.001 
(attributable 
LoS after 
adjustment) 
+13.3%, 
p=0.06 
+$38,917, 
p<0.001 
(unadjusted), 
+$29,379, 
p<0.001 
(attributable 
cost after 
adjustment) 
 
Pelz RK et al, USA VRE in ICU 1996 - 3.5 days +30% (NSD) - $17,947  
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2002 (75) (NSD) (ICU), 
+ 5 days 
(NSD) 
(overall) 
(NSD)  
Engemann JJ 
et al, 2003 
(76) 
USA MRSA 2000 +9 days post-
surgery 
(median) 
+14% + $39,572, 
p<0.001 
(median, 
unadjusted), 
+$13,901, 
p=0.03 
attributable 
cost after 
adjustment 
 
McHugh CG 
et al, 2004 
(77) 
USA MRSA 1999 +3.5 days, 
p>0.1 
(median) 
 +$36,221, 
p=0.0003 
(accrued 
charges) 
 
Wilson SJ et 
al, 2004 (78) 
USA Multidrug-
resistant 
Acinetobacter 
baumannii 
2001 +11.2days, 
p=0.06 
 +$98,575, 
p<0.01 
 
Cosgrove SE 
et al, 2005 
(79) 
USA MRSA 2000 +2 days, 
p=0.045 
(unadjusted), 
+2 days 
(adjusted) 
+ 3.1%, 
p=0.53 
+ $7,212, 
p=0.008 
(charges, 
unadjusted) 
+$6,916, 
p=0.017 
(attributable 
cost after 
adjustment) 
 
Lodise TP 
and 
USA MRSA 2001 +6.4 days, 
p<0.001 
+24%, 
p=0.001 
+$11,548, 
p<0.001 
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McKinnon PS, 
2005 (80) 
(undadjusted), 
+4.9days, 
p=0.005 
(adjusted) 
(unadjusted 
infection 
related 
mortality), 
NSD 
(adjusted) 
(unadjusted), 
+$9,909, 
p=0.001 
(adjusted) 
Reed SD et 
al, 2005 (81) 
USA MRSA 2001 + 7.3 days, 
p<0.0001 
+22.8%, 
p=0.005 (after 
12 weeks) 
+$12,231, 
p<0.0001 
(initial 
hospitalisation), 
+$13852, 
p<0.0001 (after 
12 weeks) 
 
Smith et al, 
2005 (62) 
UK MRSA 1995    £3-11bn 
Schwaber MJ 
et al, 2006 
(82) 
Israel ESBL-producing 
Escherichia coli, 
Klebsiella spp., or 
Proteus spp. 
 + 6 days, 
p<0.001 
(unadjusted), 
Odds ratio 
3.6, p=0.008 
(after 
adjustment for 
counfounding) 
+17%, p=0.01 +41,971 Israeli 
Shekels 
(unadjusted), 
+13,417 
Shekels (mean 
attributable 
cost after 
adjustment) 
 
Asche C et al, 
2008 (83) 
USA Community 
acquired 
pneumonia 
2005    Treatment 
costs 33.1% 
lower in areas 
where 
resistance 
levels were 
lower than 
25% 
Alam M, et al, UK Escherichia 2004   + £3.62  
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2009 (84) coli UTIs (p=0.006) 
Anderson D 
et al, 2009 
(85) 
USA MRSA  +6 days, 
p=0.003 
+2.7%, p=0.15 +$23362, 
p=0.001 
 
Ben-David D 
et al, 2009 
(86) 
USA MRSA  +10 days, 
p=0.003 (after 
infection, ICU 
patients), +4 
days, p=0.3 
(after 
infection, 
general unit 
patients) 
+7%, p=0.3 +$71,715, 
p<0.001 (ICU 
patients), 
+$18,278 
(general unit 
patients) 
 
Roberts R, et 
al, 2009 (87) 
USA All 
antimicrobial 
resistant 
infections 
2008 +6.4 – 12.7 
days 
+6.5% 
attributable 
mortality rate 
from ARI 
alone 
+ $18,588-
$29,069 
+ $10.7 - $15 
million 
Rubio-Terres 
C et al, 2009 
(88) 
Spain MRSA 2006 +2.2 days 
(NSD) 
+14.4%, 
p=0.005 
+€1,205 
(significance 
not given) 
 
Filice GA et 
al, 2010 (89) 
USA MRSA 2007 +10 days, 
p<0.001 
(median) 
+12.1, 
p<0.001 
+$18,734, 
p<0.001 
(median, 
unadjusted); 
adjusted costs 
remain of 
similar order  
 
Mauldin PD et 
al, 2010 (90) 
USA Acineobacter 
spp, 
Enterobacter 
spp, 
2008 + 5 days 
(median) 
(p<0.006) 
 +$38,121 
(p<0.0001) 
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Escherichia 
coli, Klebsiella 
spp, 
Pseudomonas 
spp. 
Parvizi J et al, 
2010 (91) 
USA Methicillin 
Resistant 
Periprosthetic 
Joint 
Infections 
2009 +16.7 days, 
p<0.0001 
 +$39,211, 
p<0.0001 (SD) 
 
Salgado FXC 
et al, 2011 
(92) 
Brazil MDRO in ICU 2010 Significant 
correlation 
MDRO and 
LoS (p<=0.01)
 Significant 
correlation 
MDRO and 
cost (p<=0.01) 
 
Reddy S et al, 
2011 (93) 
UK Ciproflaxin 
resistant 
Enteric fever 
n/a +1.5days 
(NSD) 
   
SD = Significant Difference as indicated by the authors of the paper 
NSD = No Significant Difference as indicated by the authors of the paper 
 
TABLE 2: ANNUAL COST-OF-ILLNESS FOR SELECTED CONDITIONS 
 
Disease Societal cost ($bn, 2004) Reference 
Antimicrobial resistance   55 (top estimate from 
2011) 
94 
Alzheimer's Disease   70 95 
Asthma   16 96 
Cancer (all) 185 97 
Cardiovascular disease 380 98 
Diabetes 145 99 
Mental disorders 260 100 
Motor vehicle accidents 270 101 
Musculoskeletal conditions 300 102 
Occupational injury and illness 266 103 
Skin disease   48 104 
Substance abuse 195 105 
Urinary incontinence   23 106 
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APPENDIX 1: Further details of methods for the literature review 
 
In line with the DH brief, the purpose of the literature review was to conduct a short 
review describing the economic burden (cost impact) of antimicrobial resistance.  An 
earlier systematic literature review concerning the economics of resistance, and 
published in 2002, had considered this as one among a number of questions relating 
to the economics of antimicrobial resistance.  At the time little evidence relating to 
this issue was found.  There appeared to have been, however, a growth in this 
literature over recent years, hence the focus on this particular question.   
 
 
Search Process 
 
Stage 1: Electronic bibliographic database searching on generic terminology 
 
Initial searching of electronic databases utilised key terms taken from the earlier 
review, searching on combinations of terms related to antimicrobial, resistance and 
costs.  Given the limited resources, both financially and in terms of time, the 
searching of databases was limited to Web of Science and Medline and to searches 
on titles. Specific terms included were: 
 
! resistan* 
IN COMBINATION WITH  
! *biotic* OR *microb* OR *virus 
IN COMBINATION WITH  
! cost* OR econ* OR resourc* 
 
Searches were conducted in June 2012. 
 
 
Stage 2/4: Citation searching 
 
Reference lists of papers selected for the review were scanned to identify any further 
papers.  Review papers identified through the review were also used in citation 
searching, both at this stage and following stage 3 searching.  
 
 
Stage 3: Further electronic bibliographic database searching relating to specific 
terminology 
 
Searches of citation lists of both empirical papers identified in Search 1 and key 
review papers, indicated that there were clearly papers relating to evidence about 
the costs of resistance in relation to particular micro-organisms that were being 
missed because of the lack of inclusion of specific terminology related to the relevant 
micro-organisms and/or the relevant antimicrobials.  Again, given limited resources, 
it was not feasible to search on all possible micro-organism names and all potential 
drugs.  Instead, a second search aimed to focus on two of the most studied and 
potentially more serious current resistant infections: Methicillin-resistant 
Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococcus (VRE),and 
these terms were added to the search and combined with the economic terms.   
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Inclusion criteria 
 
There were six inclusion criteria for the review.   
 
1.  Papers providing EITHER 
 
(i) empirical evidence on the economic impact of antimicrobial resistance 
obtained through primary data collection 
 
OR  
 
(ii) empirical evidence on the economic impact of antimicrobial resistance 
obtained through secondary modelling 
 
2. Containing information on any of length of stay, mortality, patient cost and/or 
societal cost that may be attributable to AMR 
 
3. For primary studies, inclusion of a control group of those with a susceptible 
infection. 
 
4. Publication since 2000 (the cut-off date for the earlier review) 
 
5. Publication in the English-language 
 
6. Publication in peer-reviewed journals 
 
With regard to the third inclusion criterion, the choice of the control group of those 
with a susceptible infection was made as the aim was to focus on the costs of 
resistance rather than the costs of infection per se. 
 
Other economic aspects of the antimicrobial resistance problem, such as the cost-
effectiveness of alternative control strategies, were not included.  
 
Review papers were not selected for inclusion in the review, but where these were 
identified they were accessed for the purpose of citation tracking. 
 
As part of the aim was to determine the extent of evidence available, studies were 
not accepted or rejected on the basis of any quality criteria.   
 
 
Identification of papers 
 
Papers in the stage 1 search were initially identified from abstracts obtained in the 
literature search and screened by three individuals, one of whom (JC) was expert in 
the subject area.  Papers that were obtained were then read and a final decision 
made on whether they should be included in the review.  Following the citation 
searches and subsequent database searching, a number of additional papers were 
selected.   
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Data extraction 
 
Standardised data extraction forms, based on the earlier systematic review, were 
utilised.  The following data were extracted for each study: 
Basic data: 
! Title of paper 
! Authors 
! Year of publication 
! Country of origin 
! Type of Study (primary data/modelling of secondary data) 
! If empirical, sample size and sample selection criteria 
! If modelling, type of modelling 
! Type of micro-organism 
! Type of drug 
Costs 
! Perspective for costs 
! Year of cost data 
! Currency used 
! Time period over which costs collected 
! Discounting (rate or N/A) 
Resource Use collection 
! Items collected in relation to: 
o Health Service 
o Social Services 
o Patient/family 
o Other (including lost productivity) 
! Methodological issues in relation to each of these areas 
Valuation of resource use 
! Classification of methods of valuation for each resource use item according to 
method of valuation 
o National publications (e.g. BNF for drug use in the UK) 
o Local costs (e.g. hospital finance department) 
o Detailed costing (e.g. bottom up, item by item costs) 
! Methodological issues in relation to methods of valuation 
Summary of results 
! Given in narrative form, and focusing on length of stay, mortality, patient cost 
and/or societal cost. 
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Findings 
 
In total, the review identified 24 relevant papers.  The findings from the review are 
summarised in the report and table 1 provides details from the individual studies 
included.  
 
It should be emphasised that, because of the lack of resources for a full systematic 
review, including searching for all combinations of micro-organisms and drugs, the 
totality of this literature is almost certainly under-estimated.  In terms, however, of 
general estimates of the overall burden of resistance, relevant studies should have 
been captured during the stage 1 search, and the studies on MRSA and VRE give a 
flavour of the relevant literature.  
 
